Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy

Cerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascula...

Full description

Bibliographic Details
Main Authors: Joseph O. Ojo, Jon M. Reed, Gogce Crynen, Prashanthi Vallabhaneni, James Evans, Benjamin Shackleton, Maximillian Eisenbaum, Charis Ringland, Anastasia Edsell, Michael Mullan, Fiona Crawford, Corbin Bachmeier
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2021.658605/full
id doaj-413c822661384db6ab23f184dc5ed3cf
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Joseph O. Ojo
Joseph O. Ojo
Joseph O. Ojo
Jon M. Reed
Jon M. Reed
Gogce Crynen
Prashanthi Vallabhaneni
James Evans
Benjamin Shackleton
Benjamin Shackleton
Maximillian Eisenbaum
Maximillian Eisenbaum
Charis Ringland
Charis Ringland
Anastasia Edsell
Michael Mullan
Michael Mullan
Fiona Crawford
Fiona Crawford
Fiona Crawford
Corbin Bachmeier
Corbin Bachmeier
Corbin Bachmeier
spellingShingle Joseph O. Ojo
Joseph O. Ojo
Joseph O. Ojo
Jon M. Reed
Jon M. Reed
Gogce Crynen
Prashanthi Vallabhaneni
James Evans
Benjamin Shackleton
Benjamin Shackleton
Maximillian Eisenbaum
Maximillian Eisenbaum
Charis Ringland
Charis Ringland
Anastasia Edsell
Michael Mullan
Michael Mullan
Fiona Crawford
Fiona Crawford
Fiona Crawford
Corbin Bachmeier
Corbin Bachmeier
Corbin Bachmeier
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
Frontiers in Aging Neuroscience
cerebrovasculature
Alzheimers disease
cerebral amyloid angiopathy
endothelial cells
mural cells
proteomics
author_facet Joseph O. Ojo
Joseph O. Ojo
Joseph O. Ojo
Jon M. Reed
Jon M. Reed
Gogce Crynen
Prashanthi Vallabhaneni
James Evans
Benjamin Shackleton
Benjamin Shackleton
Maximillian Eisenbaum
Maximillian Eisenbaum
Charis Ringland
Charis Ringland
Anastasia Edsell
Michael Mullan
Michael Mullan
Fiona Crawford
Fiona Crawford
Fiona Crawford
Corbin Bachmeier
Corbin Bachmeier
Corbin Bachmeier
author_sort Joseph O. Ojo
title Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
title_short Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
title_full Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
title_fullStr Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
title_full_unstemmed Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
title_sort molecular pathobiology of the cerebrovasculature in aging and in alzheimers disease cases with cerebral amyloid angiopathy
publisher Frontiers Media S.A.
series Frontiers in Aging Neuroscience
issn 1663-4365
publishDate 2021-05-01
description Cerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascular-coupling. The sequelae of molecular events leading to these early pathogenic changes remains elusive. To address this, we conducted a comprehensive in-depth molecular characterization of the proteomic changes in enriched cerebrovessel fractions isolated from the inferior frontal gyrus of autopsy AD cases with low (85.5 ± 2.9 yrs) vs. high (81 ± 4.4 yrs) CAA score, aged-matched control (87.4 ± 1.5 yrs) and young healthy control (47 ± 3.3 yrs) cases. We employed a 10-plex tandem isobaric mass tag approach in combination with our ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method. Enriched cerebrovascular fractions showed very high expression levels of proteins specific to endothelial cells, mural cells (pericytes and smooth muscle cells), and astrocytes. We observed 150 significantly regulated proteins in young vs. aged control cerebrovessels. The top pathways significantly modulated with aging included chemokine, reelin, HIF1α and synaptogenesis signaling pathways. There were 213 proteins significantly regulated in aged-matched control vs. high CAA cerebrovessels. The top three pathways significantly altered from this comparison were oxidative phosphorylation, Sirtuin signaling pathway and TCA cycle II. Comparison between low vs. high CAA cerebrovessels identified 84 significantly regulated proteins. Top three pathways significantly altered between low vs. high CAA cerebrovessels included TCA Cycle II, Oxidative phosphorylation and mitochondrial dysfunction. Notably, high CAA cases included more advanced AD pathology thus cerebrovascular effects may be driven by the severity of amyloid and Tangle pathology. These descriptive proteomic changes provide novel insights to explain the age-related and AD-related cerebrovascular changes contributing to AD pathogenesis. Particularly, disturbances in energy bioenergetics and mitochondrial biology rank among the top AD pathways altered in cerebrovessels. Targeting these failed mechanisms in endothelia and mural cells may provide novel disease modifying targets for developing therapeutic strategies against cerebrovascular deterioration and promoting cerebral perfusion in AD. Our future work will focus on interrogating and validating these novel targets and pathways and their functional significance.
topic cerebrovasculature
Alzheimers disease
cerebral amyloid angiopathy
endothelial cells
mural cells
proteomics
url https://www.frontiersin.org/articles/10.3389/fnagi.2021.658605/full
work_keys_str_mv AT josephoojo molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT josephoojo molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT josephoojo molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT jonmreed molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT jonmreed molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT gogcecrynen molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT prashanthivallabhaneni molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT jamesevans molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT benjaminshackleton molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT benjaminshackleton molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT maximillianeisenbaum molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT maximillianeisenbaum molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT charisringland molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT charisringland molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT anastasiaedsell molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT michaelmullan molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT michaelmullan molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT fionacrawford molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT fionacrawford molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT fionacrawford molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT corbinbachmeier molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT corbinbachmeier molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
AT corbinbachmeier molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy
_version_ 1721438397091807232
spelling doaj-413c822661384db6ab23f184dc5ed3cf2021-05-17T12:49:20ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652021-05-011310.3389/fnagi.2021.658605658605Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid AngiopathyJoseph O. Ojo0Joseph O. Ojo1Joseph O. Ojo2Jon M. Reed3Jon M. Reed4Gogce Crynen5Prashanthi Vallabhaneni6James Evans7Benjamin Shackleton8Benjamin Shackleton9Maximillian Eisenbaum10Maximillian Eisenbaum11Charis Ringland12Charis Ringland13Anastasia Edsell14Michael Mullan15Michael Mullan16Fiona Crawford17Fiona Crawford18Fiona Crawford19Corbin Bachmeier20Corbin Bachmeier21Corbin Bachmeier22Roskamp Institute, Sarasota, FL, United StatesJames A. Haley Veterans' Hospital, Tampa, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United StatesRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesJames A. Haley Veterans' Hospital, Tampa, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomBay Pines VA Healthcare System, Bay Pines, FL, United StatesCerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascular-coupling. The sequelae of molecular events leading to these early pathogenic changes remains elusive. To address this, we conducted a comprehensive in-depth molecular characterization of the proteomic changes in enriched cerebrovessel fractions isolated from the inferior frontal gyrus of autopsy AD cases with low (85.5 ± 2.9 yrs) vs. high (81 ± 4.4 yrs) CAA score, aged-matched control (87.4 ± 1.5 yrs) and young healthy control (47 ± 3.3 yrs) cases. We employed a 10-plex tandem isobaric mass tag approach in combination with our ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method. Enriched cerebrovascular fractions showed very high expression levels of proteins specific to endothelial cells, mural cells (pericytes and smooth muscle cells), and astrocytes. We observed 150 significantly regulated proteins in young vs. aged control cerebrovessels. The top pathways significantly modulated with aging included chemokine, reelin, HIF1α and synaptogenesis signaling pathways. There were 213 proteins significantly regulated in aged-matched control vs. high CAA cerebrovessels. The top three pathways significantly altered from this comparison were oxidative phosphorylation, Sirtuin signaling pathway and TCA cycle II. Comparison between low vs. high CAA cerebrovessels identified 84 significantly regulated proteins. Top three pathways significantly altered between low vs. high CAA cerebrovessels included TCA Cycle II, Oxidative phosphorylation and mitochondrial dysfunction. Notably, high CAA cases included more advanced AD pathology thus cerebrovascular effects may be driven by the severity of amyloid and Tangle pathology. These descriptive proteomic changes provide novel insights to explain the age-related and AD-related cerebrovascular changes contributing to AD pathogenesis. Particularly, disturbances in energy bioenergetics and mitochondrial biology rank among the top AD pathways altered in cerebrovessels. Targeting these failed mechanisms in endothelia and mural cells may provide novel disease modifying targets for developing therapeutic strategies against cerebrovascular deterioration and promoting cerebral perfusion in AD. Our future work will focus on interrogating and validating these novel targets and pathways and their functional significance.https://www.frontiersin.org/articles/10.3389/fnagi.2021.658605/fullcerebrovasculatureAlzheimers diseasecerebral amyloid angiopathyendothelial cellsmural cellsproteomics